Esketamine hydrochloride is a Small Molecule owned by Johnson & Johnson, and is involved in 47 clinical trials, of which 41 were completed, 5 are ongoing, and 1 is planned.
Esketamine is a noncompetitive glutamate NMDA receptor (N-methyl-D-aspartate) antagonist. ketamine appears to non-competitively block N-methyl-D-aspartate (NMDA) receptors and may interact with opiod mu receptors and sigma receptors, but in the mechanism of antidepressant activity it targets the glutamate NMDA receptor. Glutamatergic system plays an important role in the neuropathology and treatment of MDD. Glutamate (L-glutamic acid) is the major excitatory neurotransmitter in the central nervous system and exerts its action through ionotropic (iGluRs) and metabotropic receptors (mGluRs).
The revenue for Esketamine hydrochloride is expected to reach a total of $10.3bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Esketamine hydrochloride NPV Report.
Esketamine hydrochloride is originated and owned by Johnson & Johnson.
Esketamine hydrochloride Overview
Esketamine hydrochloride (Spravato) is a chiral cyclohexanone derivative, acts as an anti-depressant. It is formulated as spray for nasal route of administration. Spravato is indicated, in conjunction with an oral anti depressant for the treatment of treatment-resistant depression (TRD) in adults. Spravato is indicated in combination with a SSRI or SNRI, for the treatment of major depressive disorder in adults who have not responded adequately to at least two separate courses of treatment with different antidepressants, each of adequate dose and duration, in the current moderate to severe depressive episode also indicated in combination with oral antidepressant therapy, as short-term treatment, for the rapid reduction of depressive symptoms in adult patients with a moderate to severe episode of major depressive disorder, which according to clinical judgement requires urgent psychiatric care.
Esketamine (Ketamine, S-Ketamine and JNJ-54135419) is under development for the treatment of major depressive disorder with imminent risk for suicide and treatment-resistant depression (TRD). The drug candidate is administered intranasally and sublingual route. It is a new molecular entity (NME), which acts by targeting NMDA receptor. It was also under development for the treatment of treatment-resistant depression as an intravenous formulation.
Johnson & Johnson Overview
Johnson & Johnson (J&J) researches, develops, manufactures, and sells pharmaceutical products, medical devices, and consumer products. The company provides pharmaceuticals for immune diseases, cancer, neurological disorders, infectious, cardiovascular and metabolic diseases; consumer products in oral care, baby care, beauty, over-the-counter (OTC) medicines, women’s health and wound care categories; and medical devices for use in the cardiovascular, orthopaedic, general surgery and vision care fields. J&J distributes pharmaceutical and medical products to retailers, wholesalers, health care professionals and hospitals; and offers consumer products through retail outlets and distributors. The company offers its products in the US; Europe; Asia-Pacific and Africa; and Western Hemisphere (excluding the US). J&J is headquartered in New Brunswick, New Jersey, the US.
The company reported revenues of (US Dollars) US$93,775 million for the fiscal year ended January 2021 (FY2021), an increase of 13.6% over FY2020. In FY2021, the company’s operating margin was 24.3%, compared to an operating margin of 20% in FY2020. In FY2021, the company recorded a net margin of 22.3%, compared to a net margin of 17.8% in FY2020. The company reported revenues of US$23,791 million for the third quarter ended October 2022, a decrease of 1% over the previous quarter.
Quick View – Esketamine hydrochloride
|Highest Development Stage|